Trevi Therapeutics Inc (OQ:TRVI)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 195 Church St Fl 14
NEW HAVEN CT 06510-2009
Tel: N/A
IR: See website
Key People
David P. Meeker
Chairman of the Board
Jennifer L. Good
President, Chief Executive Officer, Co-Founder, Director
Thomas R. Sciascia
Co-Founder, Chief Medical Officer
Christopher J. Seiter
Chief Financial Officer
Helena Brett-Smith
Chief Development Officer
Business Overview
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat neurologically mediated conditions. The Company is engaged in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID), in patients with Parkinson's disease. The Company is conducting a Phase 2b/3 clinical trial of nalbuphine ER. The Company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of nalbuphine ER in this population. The Company's nalbuphine ER development programs are Chronic Pruritus Programs, Prurigo Nodularis Program, Pruritus in Chronic Liver Disease Program and Uremic Pruritus Program.
Financial Overview
For the three months ended 31 March 2019, Trevi Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 20% to $6.2M. Higher net loss reflects Research and development - Balancing val increase of 43% to $3.3M (expense), General and administrative - Balancing v increase of 86% to $1.4M (expense), Stock-based compensation expense increase from $52K to $124K (expense).
Employees: 16 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $229.35M as of Mar 31, 2019
Annual revenue (TTM): $0.00M as of Mar 31, 2019
EBITDA (TTM): -$20.05M as of Mar 31, 2019
Net annual income (TTM): -$26.59M as of Mar 31, 2019
Free cash flow (TTM): -$18.54M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,771,751 as of Jun 14, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization